{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:07:26Z","timestamp":1793653646468,"version":"4.5.1"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"\n Importance<\/jats:title>\n The neutrophil-lymphocyte ratio (NLR) independently predicts atherosclerotic events and is a potential biomarker for residual inflammatory risk. Interleukin (IL) 1\u03b2 inhibition reduces the NLR, but whether inhibition of IL-6, a cytokine downstream of IL-1, also lowers the NLR is uncertain.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate whether ziltivekimab, a therapeutic monoclonal antibody targeting the IL-6 ligand, associates with a lower NLR compared with placebo.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was an exploratory post hoc analysis of Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition (RESCUE), a double-blind, randomized, placebo-controlled, phase 2 trial conducted from June 17, 2019, to January 14, 2020, with 24 weeks of follow-up. Participants were enrolled at 40 sites in the US and included adults aged 18 or older with moderate to severe chronic kidney disease and high-sensitivity C-reactive protein levels of 2 mg\/L or greater. Data were analyzed from September 28, 2021, to October 2, 2022.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomly assigned equally to placebo or ziltivekimab, 7.5 mg, 15 mg, or 30 mg, subcutaneously every 4 weeks.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the change in the NLR at 12 weeks.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 264 participants (median [IQR] age, 68 [60-75] years; 135 men [51%]; 129 women [49%]) were enrolled, of which 187 (71%) had diabetes, and 126 (48%) had known atherosclerosis. The median (IQR) change in the NLR at 12 weeks was 1.56% (IQR, \u221215.7% to 20.0%), \u221213.5% (IQR, \u221231.6% to 3.20%), \u221214.3% (IQR, \u221226.9% to 4.62%), and \u221222.4% (IQR, \u221233.3% to \u22124.27%) in the placebo, 7.5-mg, 15-mg, and 30-mg groups, respectively. The estimated treatment difference compared with placebo was \u221214.6% (95% CI, \u221224.8% to \u22124.81%;\n P<\/jats:italic>\n \u2009=\u2009.004), \u221215.3% (95% CI, \u221225.2% to \u22125.10%;\n P<\/jats:italic>\n \u2009=\u2009.004), and \u221223.6% (95% CI, \u221233.2% to \u221214.2%;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) in the 7.5-mg, 15-mg, and 30-mg groups, respectively. A similar reduction in the absolute neutrophil count was observed.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Results of this post hoc analysis of the RESCUE trial show that IL-6 ligand inhibition with ziltivekimab associates with a lower NLR, suggesting that it may disrupt multiple atherogenic inflammatory pathways, including those mediated by the myeloid cell compartment. The NLR may have use in monitoring ziltivekimab\u2019s efficacy should it be introduced into clinical practice.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamacardio.2022.4277","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T11:33:12Z","timestamp":1669807992000},"page":"177","source":"Crossref","is-referenced-by-count":65,"title":["Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio"],"prefix":"10.1001","volume":"8","author":[{"given":"Nicholas H.","family":"Adamstein","sequence":"first","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine and Cardiovascular Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Hein","family":"Cornel","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Davidson","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medicine, University of Chicago Medicine, Pritzker School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"de Remigis","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Jensen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Divisions of Preventive Medicine and Cardiovascular Diseases, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"hbr220010r1","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"hbr220010r2","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction.","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"hbr220010r3","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease.","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"hbr220010r4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","article-title":"The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from 5 contemporary randomized trials.","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur Heart J"},{"issue":"4","key":"hbr220010r5","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1002\/ehf2.v8.4","article-title":"Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction.","volume":"8","author":"Curran","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"3","key":"hbr220010r6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1161\/STROKEAHA.120.032130","article-title":"Neutrophil-to-lymphocyte ratio predicts cerebral edema and clinical worsening early after reperfusion therapy in stroke.","volume":"52","author":"Ferro","year":"2021","journal-title":"Stroke"},{"issue":"38","key":"hbr220010r7","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signaling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"issue":"11","key":"hbr220010r8","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease.","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ Res"},{"issue":"15","key":"hbr220010r9","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction.","volume":"77","author":"Broch","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"10289","key":"hbr220010r10","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"hbr220010r11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s44161-021-00002-8","article-title":"Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease.","volume":"1","author":"Rohde","year":"2022","journal-title":"Nat Cardiovasc Res"},{"issue":"12","key":"hbr220010r12","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1093\/cvr\/cvab302","article-title":"Neutrophils in cardiovascular disease: warmongers, peacemakers, or both?","volume":"118","author":"Sreejit","year":"2022","journal-title":"Cardiovasc Res"},{"issue":"0","key":"hbr220010r13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cvr\/cvab337","article-title":"Interleukin-1\u00df suppression dampens inflammatory leukocyte production and uptake in atherosclerosis.","volume":"0","author":"Hettwer","year":"2021","journal-title":"Cardiovasc Res"},{"key":"hbr220010r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104013","article-title":"Interleukin-6 inhibition in ST-elevation myocardial infarction: immune cell profile in the randomised ASSAIL-MI trial.","volume":"80","author":"Huse","year":"2022","journal-title":"EBioMedicine"},{"issue":"6116","key":"hbr220010r15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1126\/science.1230719","article-title":"Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure.","volume":"339","author":"Swirski","year":"2013","journal-title":"Science"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2798978\/jamacardiology_adamstein_2022_br_220010_1675366834.29925.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T11:08:30Z","timestamp":1675854510000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2798978"}},"subtitle":["A Secondary Analysis of the RESCUE Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2022.4277","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,1]]}}}